BeiGene Says BGB-16673 Gets FDA Fast Track Status for Lymphocytic Leukemia, Lymphoma
BeiGene (BGNE) said Monday that BGB-16673, received a fast track designation from the US Food and Drug Administration for potentially treating relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
The designation, with support from phase 1/2 safety and efficacy data, is to expedite FDA's review of BGB-16673 as a treatment for adults with CLL or SLL that has relapsed or did not respond to initial treatment, according to BeiGene.
Shares of the company were up 2.8% in recent Monday premarket activity.
Price: 199.23, Change: +5.41, Percent Change: +2.79
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.